1179330-52-9
Chemical Structure
SPR741
Synonym(s): NAB741
- CAS No.: 1179330-52-9
- Formula:C44H73N13O13
- Molecular Weight:992.13
IUPAC Name: (2S,3R)-2-acetamido-3-hydroxy-N-((R)-3-hydroxy-1-oxo-1-(((3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-((R)-1-hydroxyethyl)-12-isobutyl-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl)amino)propan-2-yl)butanamid
InChIKey: JBFNEVNUGGFPBQ-DDMCRLCFSA-N
SMILES: CC(N[C@@H]([C@H](O)C)C(N[C@H](CO)C(N[C@@H](CCNC([C@](N1)([H])[C@H](O)C)=O)C(N[C@@H](CCN)C(N[C@@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCN)C1=O)=O)CCN)=O)CC(C)C)=O)CC2=CC=CC=C2)=O)=O)=O)=O)=O
Biological Activity: SPR741 (NAB741) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SPR741 | 99.53% | SPR741 (NAB741) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Corbett D, et al. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00200-17. [Content Brief]
- [2]. Eckburg PB, et al. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects. Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00892-19. [Content Brief]
